Gene
POU5F1B
| Entrez Gene ID | 5462 (See on NCBI) |
| Description | POU class 5 homeobox 1B |
| Gene Synonyms | OCT4-PG1, OTF3C, OTF3P1, POU5F1P1, POU5F1P4, POU5FLC20, POU5FLC8 |
| Node consisting of this Gene | POU5F1B POU5F1P4///POU5F1P3///POU5F1B///POU5F1 POU5F1B///POU5F1 POU5F1P1 |
Networks including this gene
| GSE10320_top8000 - GSE10320 - SiGN-BN NNSR | Predicting Relapse in Favorable Histology Wilms Tumor Using Gene Expression |
| GSE10797_top8000 - GSE10797 - SiGN-BN NNSR | Transcriptomes of breast epithelium and stroma in normal reduction mammoplasty and invasive breast cancer patients. |
| GSE10810_top8000 - GSE10810 - SiGN-BN NNSR | Gene expression signatures in breast cancer distinguish phenotype charact., histological subtypes, and tumor invasivness |
| GSE11121_top8000 - GSE11121 - SiGN-BN NNSR | The humoral immune system has a key prognostic impact in node-negative breast cancer |
| GSE11582_top8000 - GSE11582 - SiGN-BN NNSR | Genetic Analysis of Human Traits In-Vitro: Drug Response and Gene Expression in Lymphoblastoid Cell Lines |
| GSE12093_top8000 - GSE12093 - SiGN-BN NNSR | The 76-gene Signature Defines High-Risk Patients that Benefit from Adjuvant Tamoxifen Therapy |
| GSE12777_top8000 - GSE12777 - SiGN-BN NNSR | Gene expression profiling of 51 human breast cancer cell lines |
| GSE13009_top8000 - GSE13009 - SiGN-BN NNSR | MCF7 EGF, HRG stimulation |
| GSE13591_top8000 - GSE13591 - SiGN-BN NNSR | Integrated genomics approach to detect allelic imbalances in multiple myeloma |
| GSE13601_top8000 - GSE13601 - SiGN-BN NNSR | Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators |
| GSE14208_top8000 - GSE14208 - SiGN-BN NNSR | Clinical response of metastatic gastric cancer patients to cisplatin and fluorouracil (CF) combination chemotherapy |
| GSE14210_top8000 - GSE14210 - SiGN-BN NNSR | Expression data from human endoscopic biopsy samples |
| GSE14764_top8000 - GSE14764 - SiGN-BN NNSR | A Prognostic Gene Expression Index in Ovarian Cancer |
| GSE14925_top8000 - GSE14925 - SiGN-BN NNSR | Expression data from Non small cell lung cancer cell lines |
| GSE15765_top8000 - GSE15765 - SiGN-BN NNSR | Identification of cholangiocarcinoma-like gene expression traits in hepatocellular carcinoma |
| GSE15852_top8000 - GSE15852 - SiGN-BN NNSR | Expression data from human breast tumors and their paired normal tissues |
| GSE17705_top8000 - GSE17705 - SiGN-BN NNSR | Endocrine Sensitivity Index Validation Dataset |
| GSE19027_top8000 - GSE19027 - SiGN-BN NNSR | Antioxidant response gene expression in the bronchial airway epithelial cells of smokers at risk for lung cancer |
| GSE19417_top8000 - GSE19417 - SiGN-BN NNSR | Human esophageal adenocarcinomas |
| GSE20181_top8000 - GSE20181 - SiGN-BN NNSR | Letrozole (Femara) early and late responses to treatment |
| GSE20189_top8000 - GSE20189 - SiGN-BN NNSR | A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma |
| GSE20194_top8000 - GSE20194 - SiGN-BN NNSR | MAQC-II Project: human breast cancer (BR) data set |
| GSE20257_top8000 - GSE20257 - SiGN-BN NNSR | Smoking-induced Disarray of the Apical Junctional Complex Gene Expression Architecture in the Human Airway Epithelium |
| GSE2034_top8000 - GSE2034 - SiGN-BN NNSR | Breast cancer relapse free survival |
| GSE20916_top8000 - GSE20916 - SiGN-BN NNSR | Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data |
| GSE2113_top8000 - GSE2113 - SiGN-BN NNSR | Plasma cell dyscrasias expression profiles associated with distinct IGH translocations in multiple myeloma |
| GSE22093_top8000 - GSE22093 - SiGN-BN NNSR | Expression data from breast cancer FNA biopsies from patients |
| GSE22541_top8000 - GSE22541 - SiGN-BN NNSR | Expression data from pulmonary metastases and primary tumors of clear-cell renal cell carcinoma (ccRCC) with different disease-free survivals |
| GSE22597_top8000 - GSE22597 - SiGN-BN NNSR | Expression data from Fine Needle Aspiration (FNA) biopsies from breast cancer patients |
| GSE23553_top8000 - GSE23553 - SiGN-BN NNSR | Gene expression changes with induction of in-vitro platinum-resistance in ovarian cancer cell lines. |
| GSE23878_top8000 - GSE23878 - SiGN-BN NNSR | Genome Wide Expression Analysis of Middle Eastern Colorectal Cancer Reveals FOXM1 as a Novel Target for Cancer Therapy |
| GSE23988_top8000 - GSE23988 - SiGN-BN NNSR | Expression data from breast cancer FNA biopsies from patients (US samples) |
| GSE25055_top8000 - GSE25055 - SiGN-BN NNSR | Discovery cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25065_top8000 - GSE25065 - SiGN-BN NNSR | Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25066_top8000 - GSE25066 - SiGN-BN NNSR | Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25136_top8000 - GSE25136 - SiGN-BN NNSR | Optimizing molecular signatures for prostate cancer recurrence |
| GSE25428_top8000 - GSE25428 - SiGN-BN NNSR | Gene expression profiles of ovarian cancer cell lines in the presence and absence of a DNA methyltransferase inhibitor |
| GSE2549_top8000 - GSE2549 - SiGN-BN NNSR | Malignant pleural mesothelioma |
| GSE2603_top8000 - GSE2603 - SiGN-BN NNSR | Subpopulations of MDA-MB-231 and Primary Breast Cancers |
| GSE26712_top8000 - GSE26712 - SiGN-BN NNSR | A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer |
| GSE2841_top8000 - GSE2841 - SiGN-BN NNSR | Expression Profiling of pheochromocytomas of various genetic origins |
| GSE28497_top8000 - GSE28497 - SiGN-BN NNSR | New markers for minimal residual disease detection in acute lymphoblastic leukemia |
| GSE2912_top8000 - GSE2912 - SiGN-BN NNSR | Molecular classification of multiple myeloma |
| GSE29598_top8000 - GSE29598 - SiGN-BN NNSR | A Methodology for Utilization of Predictive Genomic Signatures in FFPE Samples |
| GSE3143_top8000 - GSE3143 - SiGN-BN NNSR | Breast Cancer Dataset |
| GSE3149_top8000 - GSE3149 - SiGN-BN NNSR | Ovarian Cancer Dataset |
| GSE31519_top8000 - GSE31519 - SiGN-BN NNSR | A Clinically Relevant Gene Signature in Triple-Negative and Basal-Like Breast Cancer |
| GSE31547_top8000 - GSE31547 - SiGN-BN NNSR | MSKCC-A Primary Lung Cancer Specimens |
| GSE31552_top8000 - GSE31552 - SiGN-BN NNSR | Expression Data from human Lung tissue of Patients with Non Small Cell Lung Cancer (NSCLC) |
| GSE3167_top8000 - GSE3167 - SiGN-BN NNSR | Classification of carcinoma in situ lesions in human bladder cancer |
| GSE32269_top8000 - GSE32269 - SiGN-BN NNSR | Expression data for primary localized prostate cancer versus castration-resistant bone metastatic prostate cancer |
| GSE3726_top8000 - GSE3726 - SiGN-BN NNSR | Prognostic gene signatures can be measured with samples stored in RNAlater |
| GSE4115_top8000 - GSE4115 - SiGN-BN NNSR | Airway Epithelial Gene Expression Diagnostic for the Evaluation of Smokers with Suspect Lung Cancer |
| GSE4573_top8000 - GSE4573 - SiGN-BN NNSR | Gene expression signatures for predicting prognosis of squamous cell lung carcinomas |
| GSE5327_top8000 - GSE5327 - SiGN-BN NNSR | Breast cancer relapse free survival and lung metastasis free survival |
| GSE5364_top8000 - GSE5364 - SiGN-BN NNSR | A Precisely Regulated Gene Expression Cassette Potently Modulates Metastasis and Survival in Multiple Solid Cancers |
| GSE5460_top8000 - GSE5460 - SiGN-BN NNSR | Predicting Features of Breast Cancer with Gene Expression Patterns |
| GSE5462_top8000 - GSE5462 - SiGN-BN NNSR | Letrozole (Femara) early response to treatment |
| GSE5851_top8000 - GSE5851 - SiGN-BN NNSR | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| GSE6008_top8000 - GSE6008 - SiGN-BN NNSR | Human ovarian tumors and normal ovaries |
| GSE6401_top8000 - GSE6401 - SiGN-BN NNSR | Up-regulation of translational machinery and distinct genetic subgroups characterize hyperdiploidy in multiple myeloma |
| GSE6462_top8000 - GSE6462 - SiGN-BN NNSR | MCF7 dose response |
| GSE6465_top8000 - GSE6465 - SiGN-BN NNSR | Expression data of Hepatocellular Carcinoma |
| GSE6477_top8000 - GSE6477 - SiGN-BN NNSR | Expression data from different stages of plasma cell neoplasm |
| GSE6481_top8000 - GSE6481 - SiGN-BN NNSR | Gene Expression Analysis of Soft Tissue Sarcomas: Characterization & Reclassification of Malignant Fibrous Histiocytoma |
| GSE6691_top8000 - GSE6691 - SiGN-BN NNSR | Gene expression profiling of B lymphocytes and plasma cells from WaldenstrÖm’s macroglobulinemia. |
| GSE6956_top8000 - GSE6956 - SiGN-BN NNSR | Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men |
| GSE7208_top8000 - GSE7208 - SiGN-BN NNSR | Expression data from 59 human colon tumor tissue samples |
| GSE7390_top8000 - GSE7390 - SiGN-BN NNSR | Strong Time Dependence of the 76-Gene Prognostic Signature |
| GSE7670_top8000 - GSE7670 - SiGN-BN NNSR | Expression data from Lung cancer |
| GSE7849_top8000 - GSE7849 - SiGN-BN NNSR | Age-Specific Differences of Oncogenic Pathway Deregulation Seen in Human Breast Tumors |
| GSE7904_top8000 - GSE7904 - SiGN-BN NNSR | Expression data from human breast tissue |
| GSE8332_top8000 - GSE8332 - SiGN-BN NNSR | Death receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL |
| GSE8481_top8000 - GSE8481 - SiGN-BN NNSR | Various human cell types |
| GSE8546_top8000 - GSE8546 - SiGN-BN NNSR | Gene Expression Changes in Myeloma Cells Following Short Term In-vivo Drug Exposure |
| GSE8835_top8000 - GSE8835 - SiGN-BN NNSR | Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. |
| GSE9750_top8000 - GSE9750 - SiGN-BN NNSR | Identification of gene expression profiles in cervical cancer |
| GSE9936_top8000 - GSE9936 - SiGN-BN NNSR | Expression data from human breast cancer cells (MCF-7) coexpressing ERalpha and Erbeta, treated with phytoestrogens |
| GSE9992_top8000 - GSE9992 - SiGN-BN NNSR | Molecular and transcriptional characterization of chromosome 17p loss in chronic lymphocytic leukemia, experiment A |
| GSE10320_top500tf - GSE10320 - SiGN-BN HC+Bootstrap | Predicting Relapse in Favorable Histology Wilms Tumor Using Gene Expression |
| GSE10445_top500tf - GSE10445 - SiGN-BN HC+Bootstrap | MERLION LUNG CANCER STUDY |
| GSE10797_top500tf - GSE10797 - SiGN-BN HC+Bootstrap | Transcriptomes of breast epithelium and stroma in normal reduction mammoplasty and invasive breast cancer patients. |
| GSE10810_top500tf - GSE10810 - SiGN-BN HC+Bootstrap | Gene expression signatures in breast cancer distinguish phenotype charact., histological subtypes, and tumor invasivness |
| GSE11121_top500tf - GSE11121 - SiGN-BN HC+Bootstrap | The humoral immune system has a key prognostic impact in node-negative breast cancer |
| GSE11151_top500tf - GSE11151 - SiGN-BN HC+Bootstrap | Gene expression data from different types of renal tumors and normal kidneys |
| GSE11582_top500tf - GSE11582 - SiGN-BN HC+Bootstrap | Genetic Analysis of Human Traits In-Vitro: Drug Response and Gene Expression in Lymphoblastoid Cell Lines |
| GSE12093_top500tf - GSE12093 - SiGN-BN HC+Bootstrap | The 76-gene Signature Defines High-Risk Patients that Benefit from Adjuvant Tamoxifen Therapy |
| GSE12682_top500tf - GSE12682 - SiGN-BN HC+Bootstrap | Expression data from Human Kidney (HK) samples |
| GSE12945_top500tf - GSE12945 - SiGN-BN HC+Bootstrap | Expression data from colorectal cancers |
| GSE13168_top500tf - GSE13168 - SiGN-BN HC+Bootstrap | Effects of glucocorticoids and Protein Kinase A on growth factor- and 1beta- regulated gene |
| GSE13591_top500tf - GSE13591 - SiGN-BN HC+Bootstrap | Integrated genomics approach to detect allelic imbalances in multiple myeloma |
| GSE14208_top500tf - GSE14208 - SiGN-BN HC+Bootstrap | Clinical response of metastatic gastric cancer patients to cisplatin and fluorouracil (CF) combination chemotherapy |
| GSE14210_top500tf - GSE14210 - SiGN-BN HC+Bootstrap | Expression data from human endoscopic biopsy samples |
| GSE14764_top500tf - GSE14764 - SiGN-BN HC+Bootstrap | A Prognostic Gene Expression Index in Ovarian Cancer |
| GSE14814_top500tf - GSE14814 - SiGN-BN HC+Bootstrap | Prognostic and Predictive Gene Signature for Adjuvant Chemotherapy in Resected Non-Small Cell Lung Cancer |
| GSE14925_top500tf - GSE14925 - SiGN-BN HC+Bootstrap | Expression data from Non small cell lung cancer cell lines |
| GSE15765_top500tf - GSE15765 - SiGN-BN HC+Bootstrap | Identification of cholangiocarcinoma-like gene expression traits in hepatocellular carcinoma |
| GSE15852_top500tf - GSE15852 - SiGN-BN HC+Bootstrap | Expression data from human breast tumors and their paired normal tissues |
| GSE16515_top500tf - GSE16515 - SiGN-BN HC+Bootstrap | Expression data from Mayo Clinic Pancreatic Tumor and Normal samples |
| GSE17705_top500tf - GSE17705 - SiGN-BN HC+Bootstrap | Endocrine Sensitivity Index Validation Dataset |
| GSE17920_top500tf - GSE17920 - SiGN-BN HC+Bootstrap | Expression data of diagnostic biopsy samples from Hodgkin lymphoma patients |
| GSE18497_top500tf - GSE18497 - SiGN-BN HC+Bootstrap | Diagnosis-relapse in ALL |
| GSE18864_top500tf - GSE18864 - SiGN-BN HC+Bootstrap | Tumor expression data from neoadjuvant trial of cisplatin monotherapy in triple negative breast cancer patients |
| GSE19027_top500tf - GSE19027 - SiGN-BN HC+Bootstrap | Antioxidant response gene expression in the bronchial airway epithelial cells of smokers at risk for lung cancer |
| GSE20181_top500tf - GSE20181 - SiGN-BN HC+Bootstrap | Letrozole (Femara) early and late responses to treatment |
| GSE20189_top500tf - GSE20189 - SiGN-BN HC+Bootstrap | A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma |
| GSE20194_top500tf - GSE20194 - SiGN-BN HC+Bootstrap | MAQC-II Project: human breast cancer (BR) data set |
| GSE20271_top500tf - GSE20271 - SiGN-BN HC+Bootstrap | Expression data from breast cancer FNA biopsies from patients |
| GSE2034_top500tf - GSE2034 - SiGN-BN HC+Bootstrap | Breast cancer relapse free survival |
| GSE20916_top500tf - GSE20916 - SiGN-BN HC+Bootstrap | Modeling oncogenic signaling in colon tumors by multidirectional analyses of microarray data |
| GSE2113_top500tf - GSE2113 - SiGN-BN HC+Bootstrap | Plasma cell dyscrasias expression profiles associated with distinct IGH translocations in multiple myeloma |
| GSE22093_top500tf - GSE22093 - SiGN-BN HC+Bootstrap | Expression data from breast cancer FNA biopsies from patients |
| GSE22541_top500tf - GSE22541 - SiGN-BN HC+Bootstrap | Expression data from pulmonary metastases and primary tumors of clear-cell renal cell carcinoma (ccRCC) with different disease-free survivals |
| GSE22597_top500tf - GSE22597 - SiGN-BN HC+Bootstrap | Expression data from Fine Needle Aspiration (FNA) biopsies from breast cancer patients |
| GSE23553_top500tf - GSE23553 - SiGN-BN HC+Bootstrap | Gene expression changes with induction of in-vitro platinum-resistance in ovarian cancer cell lines. |
| GSE23988_top500tf - GSE23988 - SiGN-BN HC+Bootstrap | Expression data from breast cancer FNA biopsies from patients (US samples) |
| GSE25055_top500tf - GSE25055 - SiGN-BN HC+Bootstrap | Discovery cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25065_top500tf - GSE25065 - SiGN-BN HC+Bootstrap | Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25066_top500tf - GSE25066 - SiGN-BN HC+Bootstrap | Genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| GSE25136_top500tf - GSE25136 - SiGN-BN HC+Bootstrap | Optimizing molecular signatures for prostate cancer recurrence |
| GSE25428_top500tf - GSE25428 - SiGN-BN HC+Bootstrap | Gene expression profiles of ovarian cancer cell lines in the presence and absence of a DNA methyltransferase inhibitor |
| GSE2549_top500tf - GSE2549 - SiGN-BN HC+Bootstrap | Malignant pleural mesothelioma |
| GSE2603_top500tf - GSE2603 - SiGN-BN HC+Bootstrap | Subpopulations of MDA-MB-231 and Primary Breast Cancers |
| GSE26549_top500tf - GSE26549 - SiGN-BN HC+Bootstrap | Gene Expression Profiling Predicts the Development of Oral Cancer |
| GSE26712_top500tf - GSE26712 - SiGN-BN HC+Bootstrap | A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer |
| GSE27562_top500tf - GSE27562 - SiGN-BN HC+Bootstrap | Expression data from human PBMCs from breast cancer patients and controls |
| GSE2841_top500tf - GSE2841 - SiGN-BN HC+Bootstrap | Expression Profiling of pheochromocytomas of various genetic origins |
| GSE28497_top500tf - GSE28497 - SiGN-BN HC+Bootstrap | New markers for minimal residual disease detection in acute lymphoblastic leukemia |
| GSE3149_top500tf - GSE3149 - SiGN-BN HC+Bootstrap | Ovarian Cancer Dataset |
| GSE31519_top500tf - GSE31519 - SiGN-BN HC+Bootstrap | A Clinically Relevant Gene Signature in Triple-Negative and Basal-Like Breast Cancer |
| GSE31547_top500tf - GSE31547 - SiGN-BN HC+Bootstrap | MSKCC-A Primary Lung Cancer Specimens |
| GSE31552_top500tf - GSE31552 - SiGN-BN HC+Bootstrap | Expression Data from human Lung tissue of Patients with Non Small Cell Lung Cancer (NSCLC) |
| GSE3167_top500tf - GSE3167 - SiGN-BN HC+Bootstrap | Classification of carcinoma in situ lesions in human bladder cancer |
| GSE32269_top500tf - GSE32269 - SiGN-BN HC+Bootstrap | Expression data for primary localized prostate cancer versus castration-resistant bone metastatic prostate cancer |
| GSE3726_top500tf - GSE3726 - SiGN-BN HC+Bootstrap | Prognostic gene signatures can be measured with samples stored in RNAlater |
| GSE4115_top500tf - GSE4115 - SiGN-BN HC+Bootstrap | Airway Epithelial Gene Expression Diagnostic for the Evaluation of Smokers with Suspect Lung Cancer |
| GSE4536_top500tf - GSE4536 - SiGN-BN HC+Bootstrap | Tumor stem cells more closely mirror the phenotype and genotype of primary human tumors than do cancer cell lines |
| GSE4573_top500tf - GSE4573 - SiGN-BN HC+Bootstrap | Gene expression signatures for predicting prognosis of squamous cell lung carcinomas |
| GSE5327_top500tf - GSE5327 - SiGN-BN HC+Bootstrap | Breast cancer relapse free survival and lung metastasis free survival |
| GSE5364_top500tf - GSE5364 - SiGN-BN HC+Bootstrap | A Precisely Regulated Gene Expression Cassette Potently Modulates Metastasis and Survival in Multiple Solid Cancers |
| GSE5460_top500tf - GSE5460 - SiGN-BN HC+Bootstrap | Predicting Features of Breast Cancer with Gene Expression Patterns |
| GSE5462_top500tf - GSE5462 - SiGN-BN HC+Bootstrap | Letrozole (Femara) early response to treatment |
| GSE5851_top500tf - GSE5851 - SiGN-BN HC+Bootstrap | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| GSE5900_top500tf - GSE5900 - SiGN-BN HC+Bootstrap | Gene Expression of Bone Marrow Plasma Cells from Healthy Donors (N=22), MGUS (N=44), and Smoldering Myeloma (N=12) |
| GSE6008_top500tf - GSE6008 - SiGN-BN HC+Bootstrap | Human ovarian tumors and normal ovaries |
| GSE6338_top500tf - GSE6338 - SiGN-BN HC+Bootstrap | Gene expression analysis of Peripheral T-cell Lymphoma/Unspecified |
| GSE6365_top500tf - GSE6365 - SiGN-BN HC+Bootstrap | Distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma |
| GSE6401_top500tf - GSE6401 - SiGN-BN HC+Bootstrap | Up-regulation of translational machinery and distinct genetic subgroups characterize hyperdiploidy in multiple myeloma |
| GSE6462_top500tf - GSE6462 - SiGN-BN HC+Bootstrap | MCF7 dose response |
| GSE6465_top500tf - GSE6465 - SiGN-BN HC+Bootstrap | Expression data of Hepatocellular Carcinoma |
| GSE6477_top500tf - GSE6477 - SiGN-BN HC+Bootstrap | Expression data from different stages of plasma cell neoplasm |
| GSE6481_top500tf - GSE6481 - SiGN-BN HC+Bootstrap | Gene Expression Analysis of Soft Tissue Sarcomas: Characterization & Reclassification of Malignant Fibrous Histiocytoma |
| GSE6691_top500tf - GSE6691 - SiGN-BN HC+Bootstrap | Gene expression profiling of B lymphocytes and plasma cells from WaldenstrÖm’s macroglobulinemia. |
| GSE7208_top500tf - GSE7208 - SiGN-BN HC+Bootstrap | Expression data from 59 human colon tumor tissue samples |
| GSE7670_top500tf - GSE7670 - SiGN-BN HC+Bootstrap | Expression data from Lung cancer |
| GSE7904_top500tf - GSE7904 - SiGN-BN HC+Bootstrap | Expression data from human breast tissue |
| GSE8332_top500tf - GSE8332 - SiGN-BN HC+Bootstrap | Death receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL |
| GSE8481_top500tf - GSE8481 - SiGN-BN HC+Bootstrap | Various human cell types |
| GSE9169_top500tf - GSE9169 - SiGN-BN HC+Bootstrap | Gene expression during neuronal differentiation in two subtypes of SH-SY5Y |
| GSE9992_top500tf - GSE9992 - SiGN-BN HC+Bootstrap | Molecular and transcriptional characterization of chromosome 17p loss in chronic lymphocytic leukemia, experiment A |
| GSE8218_top500tf - GSE8218 - SiGN-BN HC+Bootstrap | Gene expression data from prostate cancer samples |
| GSE9750_top500tf - GSE9750 - SiGN-BN HC+Bootstrap | Identification of gene expression profiles in cervical cancer |
| GSE9936_top500tf - GSE9936 - SiGN-BN HC+Bootstrap | Expression data from human breast cancer cells (MCF-7) coexpressing ERalpha and Erbeta, treated with phytoestrogens |
(163 networks)
